Compile Data Set for Download or QSAR
Report error Found 348 Enz. Inhib. hit(s) with all data for entry = 5880
TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98411(US8481733, 223)
Affinity DataIC50: 30nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98237(US8481733, 49)
Affinity DataIC50: 35.2nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98449(US8481733, 261)
Affinity DataIC50: 36.9nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98341(US8481733, 219)
Affinity DataIC50: 43.9nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98208(US8481733, 20)
Affinity DataIC50: 48.7nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98200(US8481733, 11)
Affinity DataIC50: 50nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98450(US8481733, 262)
Affinity DataIC50: 50nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98274(US8481733, 86)
Affinity DataIC50: 58.9nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98238(US8481733, 50)
Affinity DataIC50: 60.4nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98343(US8481733, 155)
Affinity DataIC50: 66.7nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98260(US8481733, 72)
Affinity DataIC50: 75nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98426(US8481733, 238)
Affinity DataIC50: 75.1nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98226(US8481733, 38)
Affinity DataIC50: 86.5nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98209(US8481733, 21)
Affinity DataIC50: 88nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98297(US8481733, 109)
Affinity DataIC50: 88.6nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98236(US8481733, 48)
Affinity DataIC50: 90nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98376(US8481733, 188)
Affinity DataIC50: 95.2nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98195(US8481733, 6)
Affinity DataIC50: 95.8nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98259(US8481733, 71)
Affinity DataIC50: 100nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98370(US8481733, 182)
Affinity DataIC50: 109nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98446(US8481733, 258)
Affinity DataIC50: 110nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98440(US8481733, 252)
Affinity DataIC50: 112nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98280(US8481733, 92)
Affinity DataIC50: 115nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98295(US8481733, 107)
Affinity DataIC50: 117nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98282(US8481733, 94)
Affinity DataIC50: 119nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98347(US8481733, 159)
Affinity DataIC50: 122nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98474(US8481733, 286)
Affinity DataIC50: 136nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98296(US8481733, 108)
Affinity DataIC50: 137nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98428(US8481733, 240)
Affinity DataIC50: 139nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98293(US8481733, 105)
Affinity DataIC50: 140nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98336(US8481733, 148)
Affinity DataIC50: 145nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM50199622(CHEMBL245408 | US8481733, Comparator 5 | 3-cyclobu...)
Affinity DataIC50: 148nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98199(US8481733, 10)
Affinity DataIC50: 153nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98424(US8481733, 236)
Affinity DataIC50: 154nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98459(US8481733, 271)
Affinity DataIC50: 176nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98279(US8481733, 91)
Affinity DataIC50: 178nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98257(US8481733, 69)
Affinity DataIC50: 181nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98235(US8481733, 47)
Affinity DataIC50: 181nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98276(US8481733, 88)
Affinity DataIC50: 183nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98329(US8481733, 141)
Affinity DataIC50: 183nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98351(US8481733, 163)
Affinity DataIC50: 188nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98253(US8481733, 65)
Affinity DataIC50: 188nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98465(US8481733, 277)
Affinity DataIC50: 197nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98460(US8481733, 272)
Affinity DataIC50: 199nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98464(US8481733, 276)
Affinity DataIC50: 201nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98255(US8481733, 67)
Affinity DataIC50: 203nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98234(US8481733, 46)
Affinity DataIC50: 205nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98192(US8481733, 3)
Affinity DataIC50: 212nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98294(US8481733, 106)
Affinity DataIC50: 216nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

TargetActivated CDC42 kinase 1(Human)
Osi Pharmaceuticals

US Patent
LigandPNGBDBM98461(US8481733, 273)
Affinity DataIC50: 216nMAssay Description:Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15× in 4 mM DMSO were combined with 9 uL ATP so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2013
Entry Details
Go to US Patent

Displayed 1 to 50 (of 348 total ) | Next | Last >>
Jump to: